PFE Quote, Financials, Valuation and Earnings

Arvinas has a net margin of 21.63% compared to Pfizer's net margin of 43.91%. Pfizer's return on equity of 8.72% beat Arvinas's return on equity of -7.72%.

Pfizer has a consensus price target of $29.25, signalling upside risk potential of 31.27%. On the other hand Arvinas has an analysts' consensus of $22.36 which suggests that it could grow by 238.29%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Pfizer has a beta of 0.588, which suggesting that the stock is 41.208% less volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $13.7B, which are larger than Arvinas quarterly revenues of $188.8M. Pfizer's net income of $3B is higher than Arvinas's net income of $82.9M. Notably, Pfizer's price-to-earnings ratio is 16.14x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.03x versus 1.12x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.63% compared to Pfizer's net margin of -907.48%. Pfizer's return on equity of 8.72% beat Moderna's return on equity of -29.23%.

Pfizer has a consensus price target of $29.25, signalling upside risk potential of 31.27%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 93.66%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Pfizer has a beta of 0.588, which suggesting that the stock is 41.208% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $13.7B, which are larger than Moderna quarterly revenues of $107M. Pfizer's net income of $3B is higher than Moderna's net income of -$971M. Notably, Pfizer's price-to-earnings ratio is 16.14x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.03x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 21.63% compared to Pfizer's net margin of 26.7%. Pfizer's return on equity of 8.72% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Pfizer has a consensus price target of $29.25, signalling upside risk potential of 31.27%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 51.6%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Pfizer has a beta of 0.588, which suggesting that the stock is 41.208% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Regeneron Pharmaceuticals offers a yield of 0.17% to investors and pays a quarterly dividend of $0.88 per share. Pfizer pays 118.44% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $13.7B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Pfizer's net income of $3B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Pfizer's price-to-earnings ratio is 16.14x while Regeneron Pharmaceuticals's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.03x versus 4.28x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 21.63% compared to Pfizer's net margin of --. Pfizer's return on equity of 8.72% beat Viking Therapeutics's return on equity of --.

Pfizer has a consensus price target of $29.25, signalling upside risk potential of 31.27%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 227.63%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

Pfizer has a beta of 0.588, which suggesting that the stock is 41.208% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $13.7B, which are larger than Viking Therapeutics quarterly revenues of --. Pfizer's net income of $3B is higher than Viking Therapeutics's net income of -$45.6M. Notably, Pfizer's price-to-earnings ratio is 16.14x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.03x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.